Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway
P. Chopin et al., Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway, J PHARM EXP, 288(2), 1999, pp. 798-804
Citations number
70
Categorie Soggetti
Pharmacology & Toxicology
Journal title
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
The present study examined the influence of alpha-2 adrenoceptor ligands on
circling behavior in rats with unilateral 6-hydroxydopamine lesions of the
nigrostriatal pathway. The alpha-2 adrenoceptor agonists, clonidine and UK
14304, inhibited both the ipsilateral rotation induced by the indirect dop
aminergic agonist, methylphenidate, and the contralateral circling induced
by the direct dopaminergic agonist, apomorphine. In contrast, the alpha-2 a
drenoceptor antagonists, idazoxan and (+/-)-efaroxan, enhanced the circling
induced by either methylphenidate or apomorphine. The facilitating activit
y of efaroxan was stereoselective because the (+)-enantiomer mimicked the e
ffect of (+)-efaroxan, whereas the (-)-enantiomer was essentially inactive,
thus indicating a mediation by alpha-e adrenoceptors. Upon administration
alone, the above-mentioned compounds did not modify spontaneous circling be
havior, except for UK 14304, which decreased, and (+)-efaroxan, which sligh
tly increased, the ipsilateral rotation. We conclude that activation and an
tagonism of alpha-2 adrenoceptors inhibit and enhance, respectively, the ci
rcling behavior evoked by both direct and indirect dopaminergic agonists. A
lthough a modulation of dopamine release may be involved in some of these d
rug effects, the effects on apomorphine-induced circling indicate an influe
nce of alpha-2 adrenoceptor compounds on nigrostriatal neurotransmission at
sites downstream from the dopaminergic neurons themselves. These findings
support the notion of a potential benefit of alpha-2 adrenoceptor antagonis
ts in the treatment of Parkinson's disease.